Ixazomib
Overview
Ixazomib is a proteasome inhibitor used in the treatment of multiple myeloma. It is administered as a prodrug and is the first oral proteasome inhibitor developed.
API suppliers (1)
Suppliers of Ixazomib evidenced by a US FDA Type II Drug Master File or an EU Certificate of Suitability (CEP). Sources: FDA DMF list, EDQM certification database.
- CHONGQING MIDECO PHARMACEUTICAL CO LTD1 active DMF
Patent & exclusivity (US)
Per the FDA Orange Book (3 approved US products), the latest listed US patent on Ixazomib expires 20 Nov 2029. Generic API sourcing typically opens up once these lapse.
Therapeutic areas
Do you supply Ixazomib? Get in front of buyers actively sourcing it.
We route real sourcing requests from pharma buyers to vetted, verified partners — qualified leads, not just a listing. Tell us what you make and we'll be in touch about becoming a Verified Supplier Partner.
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 7 days.